Copper homeostasis and cuproptosis in cardiovascular disease therapeutics

L Yang, P Yang, GYH Lip, J Ren - Trends in pharmacological sciences, 2023 - cell.com
Copper (Cu) homeostasis is gaining increasing attention in human health as both Cu
overload and deficiency evokes pathological changes including cardiovascular diseases …

Cardioprotective properties of kaempferol: a review

Y Kamisah, J Jalil, NM Yunos, S Zainalabidin - Plants, 2023 - mdpi.com
Cardiac diseases, such as myocardial infarction and heart failure, have become a major
clinical problem globally. The accumulating data demonstrate that bioactive compounds with …

Exploring cuproptosis as a mechanism and potential intervention target in cardiovascular diseases

Y Yang, Q Feng, Y Luan, H Liu, Y Jiao, H Hao… - Frontiers in …, 2023 - frontiersin.org
Copper (Cu) is a vital trace element for maintaining human health. Current evidence
suggests that genes responsible for regulating copper influx and detoxification help …

Therapeutic use and molecular aspects of ivabradine in cardiac remodeling: A review

Y Kamisah, HH Che Hassan - International Journal of Molecular Sciences, 2023 - mdpi.com
Cardiac remodeling can cause ventricular dysfunction and progress to heart failure, a
cardiovascular disease that claims many lives globally. Ivabradine, a funny channel (I f) …

Interplay of Ferroptosis, Cuproptosis, and PANoptosis in Cancer Treatment-Induced Cardiotoxicity: Mechanisms and Therapeutic Implications

F Yang, G Zhang, N An, Q Dai, W Cho, H Shang… - Seminars in Cancer …, 2024 - Elsevier
With the prolonged survival of individuals with cancer, the emergence of cardiovascular
diseases (CVD) induced by cancer treatment has become a significant concern, ranking as …

Parkia speciosa Hassk. Empty Pod Extract Prevents Cardiomyocyte Hypertrophy by Inhibiting MAPK and Calcineurin-NFATC3 Signaling Pathways

NH Mustafa, J Jalil, MSM Saleh, S Zainalabidin… - Life, 2022 - mdpi.com
Cardiac hypertrophy is an early hallmark during the clinical course of heart failure.
Therapeutic strategies aiming to alleviate cardiac hypertrophy via the mitogen-activated …

Clinical Trials in Hypertrophic Cardiomyopathy Therapy: A Comprehensive Analysis of Trials Registered in Global Clinical Databases

H Zhang, C Yu, Y Cheng, Z Chen, M Chen… - Drug Design …, 2023 - Taylor & Francis
Background With the disappointing results associated with the use of cardiac myosin
inhibitors in the treatment of hypertrophic cardiomyopathy (HCM), the development of new …

Recent Advances in the Biomedical Applications of Copper Nanomaterial‐Mediated Cuproptosis

S Wu, Q Wang, Y Li, B Liu… - Advanced NanoBiomed …, 2024 - Wiley Online Library
Nanomedicine‐induced cancer cell death has become a prominent area of research in the
life sciences field in recent years. The concept of cuproptosis was first proposed in 2022 …

Copper ions: The invisible killer of cardiovascular disease

YM Wang, LS Feng, A Xu, XH Ma… - Molecular …, 2024 - spandidos-publications.com
Copper, a vital trace element, is indispensable for the maintenance of physiological
functioning, particularly in the cardiac system. Unlike other forms of cell death such as iron …

Developing an analytical method for quantification of trientine based on modified silver nanoparticles

M Khodadadi, A Shayanfar - BMC chemistry, 2023 - Springer
Abstract Trientine or (N, N´-bis (2-aminoethyl)-1, 2-ethanediamine (TETA) is a copper
chelator and used in Wilson's disease, is aliphatic amine that does not have UV absorbing …